Chinook Therapeutics, Inc. Common Stock
KDNY
KDNY was delisted on the 10th of August, 2023.
82 hedge funds and large institutions have $110M invested in Chinook Therapeutics, Inc. Common Stock in 2020 Q1 according to their latest regulatory filings, with 19 funds opening new positions, 21 increasing their positions, 29 reducing their positions, and 19 closing their positions.
179% more capital invested
Capital invested by funds: $39.2M → $110M (+$70.3M)
0% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 19
2% less funds holding
Funds holding: 84 → 82 (-2)
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$12.1M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$4.26M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$3.99M |
| 4 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$2.06M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$996K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$1.66M |
| 2 |
Two Sigma Investments
New York
|
-$1.08M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$893K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$730K |
| 5 |
EAM
Erste Asset Management
Vienna,
Austria
|
-$674K |
KDNY Hedge Fund Activity: Q1 2020 in Review
82 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Chinook Therapeutics, Inc. Common Stock (KDNY) for Q1 2020, worth a combined $110M — up 179% from $39.2M a quarter earlier.
Fund positioning in KDNY was balanced in Q1 2020: 19 funds opened new positions, 19 closed out, 21 added to existing stakes and 29 trimmed.
The largest buyer was Vivo Capital, opening a new position worth an estimated $12.1M. The largest seller was Goldman Sachs, cutting an estimated $1.66M.
- 82 institutional investors held Chinook Therapeutics, Inc. Common Stock (KDNY) as of Q1 2020, down from 84 in Q4 2019.
- Funds reported $110M of Chinook Therapeutics, Inc. Common Stock stock for Q1 2020, up 179% quarter-over-quarter.
- 19 funds opened new Chinook Therapeutics, Inc. Common Stock positions in Q1 2020 and 19 closed out, a net change of 0 holders.
- The largest Chinook Therapeutics, Inc. Common Stock buyer in Q1 2020 was Vivo Capital, an estimated $12.1M added.
- The largest Chinook Therapeutics, Inc. Common Stock seller in Q1 2020 was Goldman Sachs, an estimated $1.66M sold.
Based on aggregated 13F filings for Q1 2020.